Picture of Atea Pharmaceuticals logo

AVIR — Atea Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Atea Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

* Atea Pharmaceuticals Inc  AVIR.OQ  reported a quarterly
adjusted
loss of 37 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -40 cents.  The mean expectation of
three analysts for the quarter was for a loss of 49 cents per
share. Wall Street expected results to range from -56 cents
to -43 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Atea Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 37 cents​.
    * The company reported a quarterly loss of $31.15 million.
    * Atea Pharmaceuticals Inc shares had risen by 2.7% this
quarter and gained 12.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 20.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Atea
Pharmaceuticals Inc is $6.88 
This summary was machine generated from LSEG data November 8 at
09:48 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.49          -0.37          Beat
 Jun. 30 2024      -0.76          -0.48          Beat
 Mar. 31 2024      -0.61          -0.75          Missed
 Dec. 31 2023      -0.50          -0.47          Beat

Recent news on Atea Pharmaceuticals

See all news